140 related articles for article (PubMed ID: 2903379)
1. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism.
Laron Z; Klinger B; Erster B; Anin S
Lancet; 1988 Nov; 2(8621):1170-2. PubMed ID: 2903379
[TBL] [Abstract][Full Text] [Related]
2. IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF-I.
Laron Z; Klinger B; Blum WF; Silbergeld A; Ranke MB
Clin Endocrinol (Oxf); 1992 Mar; 36(3):301-4. PubMed ID: 1373347
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone and insulin-like growth factor regulate insulin-like growth factor-binding protein-1 in Laron type dwarfism, growth hormone deficiency and constitutional short stature.
Laron Z; Suikkari AM; Klinger B; Silbergeld A; Pertzelan A; Seppälä M; Koivisto VA
Acta Endocrinol (Copenh); 1992 Oct; 127(4):351-8. PubMed ID: 1280392
[TBL] [Abstract][Full Text] [Related]
4. Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome). Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes.
Wilton P
Acta Paediatr Suppl; 1992 Sep; 383():137-42. PubMed ID: 1281024
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism.
Laron Z; Klinger B; Jensen LT; Erster B
Clin Endocrinol (Oxf); 1991 Aug; 35(2):145-50. PubMed ID: 1934530
[TBL] [Abstract][Full Text] [Related]
6. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism.
Laron Z; Anin S; Klipper-Aurbach Y; Klinger B
Lancet; 1992 May; 339(8804):1258-61. PubMed ID: 1349669
[TBL] [Abstract][Full Text] [Related]
7. Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism).
Walker JL; Ginalska-Malinowska M; Romer TE; Pucilowska JB; Underwood LE
N Engl J Med; 1991 May; 324(21):1483-8. PubMed ID: 2023608
[No Abstract] [Full Text] [Related]
8. Serum prolactin in patients with Laron-type dwarfism: effect of insulin-like growth factor I.
Silbergeld A; Klinger B; Schwartz H; Laron Z
Horm Res; 1992; 37(4-5):160-4. PubMed ID: 1490658
[TBL] [Abstract][Full Text] [Related]
9. A child with phenotypic Laron dwarfism and normal somatomedin levels.
Pintor C; Loche S; Cella SG; Müller EE; Baumann G
N Engl J Med; 1989 Feb; 320(6):376-9. PubMed ID: 2913494
[No Abstract] [Full Text] [Related]
10. An update on Laron syndrome.
Laron Z
Arch Dis Child; 1993 Mar; 68(3):345-6. PubMed ID: 8466235
[No Abstract] [Full Text] [Related]
11. Clinical use of somatomedin-1: yes or no?
Laron Z
Paediatr Drugs; 1999; 1(3):155-9. PubMed ID: 10937448
[TBL] [Abstract][Full Text] [Related]
12. Laron-type dwarfism with apparently normal high affinity serum growth hormone-binding protein.
Buchanan CR; Maheshwari HG; Norman MR; Morrell DJ; Preece MA
Clin Endocrinol (Oxf); 1991 Aug; 35(2):179-85. PubMed ID: 1934534
[TBL] [Abstract][Full Text] [Related]
13. The little women of Loja--growth hormone-receptor deficiency in an inbred population of southern Ecuador.
Rosenbloom AL; Guevara Aguirre J; Rosenfeld RG; Fielder PJ
N Engl J Med; 1990 Nov; 323(20):1367-74. PubMed ID: 2233903
[TBL] [Abstract][Full Text] [Related]
14. A child with phenotypic Laron dwarfism and normal somatomedin levels.
Laron Z; Silbergeld A
N Engl J Med; 1989 Jun; 320(25):1698-9. PubMed ID: 2725626
[No Abstract] [Full Text] [Related]
15. [Laron type familial dwarfism; genetic primary somatomedin deficiency].
Pierson M; Malaprade D; Fortier G; Belleville F; Lasbennes A; Wuilbereq L
Arch Fr Pediatr; 1978 Feb; 35(2):151-64. PubMed ID: 637670
[TBL] [Abstract][Full Text] [Related]
16. Growth-stimulating effects of somatomedin-/insulin-like peptides in Snell dwarf mice.
van Buul-Offers S; Hoogerbrugge CM; Branger J; Feijlbrief M; Van den Brande JL
Horm Res; 1988; 29(5-6):229-36. PubMed ID: 3220460
[TBL] [Abstract][Full Text] [Related]
17. Tissues of the Laron dwarf are sensitive to insulin-like growth factor I but not to growth hormone.
Geffner ME; Golde DW; Lippe BM; Kaplan SA; Bersch N; Li CH
J Clin Endocrinol Metab; 1987 May; 64(5):1042-6. PubMed ID: 3031118
[TBL] [Abstract][Full Text] [Related]
18. Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism.
Laron Z; Klinger B; Erster B; Silbergeld A
Acta Endocrinol (Copenh); 1989 Oct; 121(4):603-8. PubMed ID: 2800930
[TBL] [Abstract][Full Text] [Related]
19. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment.
Laron Z; Klinger B
Horm Res; 1993; 40(1-3):16-22. PubMed ID: 8300045
[TBL] [Abstract][Full Text] [Related]
20. Effects of nutrient intake on growth, insulin-like growth factors, and their binding proteins in a Laron-type dwarf.
Crosnier H; Gourmelen M; Prévot C; Rappaport R
J Clin Endocrinol Metab; 1993 Jan; 76(1):248-50. PubMed ID: 7678425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
